<DOC>
	<DOCNO>NCT01099644</DOCNO>
	<brief_summary>The purpose study test safety new medicine call antibody 8H9 injected line abdomen peritoneum , tumor . This medicine antibody protein bind certain tumor , include DSCRT . There small number DSCRT bind 8H9 . If tumor bind 8H9 , might benefit treatment . The investigator want find effect , good and/or bad , . This antibody make mouse . Radioactive iodine bound antibody deliver radiation tumor . The investigator wish determine safety radiolabeled 8H9 different dose level . This first study use 131I-8H9 peritoneum .</brief_summary>
	<brief_title>Intraperitoneal Radioimmunotherapy With 131I-8H9 Patients With Desmoplastic Small Round Cell Tumors Other Solid Tumors Involving Peritoneum</brief_title>
	<detailed_description />
	<mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
	<criteria>Patients must diagnosis ( ) DSRCT peritoneal involvement ( b ) 8H9positive solid tumor involve peritoneum ( e.g . adrenocortical carcinoma , Wilm 's tumor ) . For tumor DSRCT , patient must history tumor progression recurrence failure achieve complete response standard therapy &lt; 20 % chance long term diseasefree survival . For tumor DSRCT , 8H9 reactivity must confirm immunohistochemistry . Patients DSCRT require measurable evaluable disease . Patients tumor DSRCT without measurable evaluable disease consider &lt; 20 % chance long term diseasefree survival . Prior Therapy : At least 4 week elapse since biologic therapy , immunotherapy . Three week elapse since last dose chemotherapy radiotherapy . Age &gt; 1 year able cooperate radiation safety restriction therapy period . Stem cell : Patients must autologous hematopoietic stem cell product cryopreserved available reinfusion 131 I8H9 treatment . The minimum dose hematopoietic stem cell 2 x 106 CD34+ cells/kg . Minimum life expectancy six week determine consent professional . Signed informed consent indicate awareness investigational nature program . Severe major organ toxicity . Renal , cardiac , hepatic , pulmonary , gastrointestinal neurologic toxicity grade 1 less ( per NCI CTC version 3 criterion ) follow exception : serum AST , ALT alkaline phosphatase ≤5 x upper limit normal ( ULN ) , serum bilirubin ≤ 3 x ULN nausea vomit ≤ grade 2 Patients myelosuppression exclude ANC ≥ 500/uL . Platelet count &gt; 50,000/ul hemoglobin &gt; 8gm/dl . Patients may receive platelet red blood cell transfusion maintain hemoglobin platelet clinical appropriate level . Patients clinically suspect dense intraperitoneal adhesion prevent adequate IP distribution . History allergy mouse protein . Patients previously treat murine monoclonal antibody exclude HAMA level &gt; 1000U/ml . Active serious infection control antibiotic . Pregnant woman woman breast feed exclude fear danger fetus/infant . Therefore negative pregnancy test require woman childbearing age , appropriate contraception use study period . Pregnancy test carry within two week prior administration radioiodinated 8H9 female childbearing age . Inability unwillingness comply radiation safety procedure protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Peritoneum</keyword>
	<keyword>Desmoplastic Small Round Cell Tumors</keyword>
	<keyword>Intraperitoneal Radioimmunotherapy</keyword>
	<keyword>131 I-8H9</keyword>
	<keyword>09-090</keyword>
</DOC>